Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) — Capital Reinvestment Ratio

Latest as of September 2025: 97.08x

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Capital Reinvestment Ratio of 97.08x as of September 2025, meaning it reinvests 97% of its operating cash flow (CN¥543.69K) in capital expenditures (CN¥52.78 Million). See net asset quality index of Suzhou Zelgen Biopharmaceuticals Co Ltd to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

97.08x

Capex / Operating Cash Flow

Operating Cash Flow

CN¥543.69K

CNY

Capital Expenditures

CN¥52.78 Million

CNY

Data as of

Sep 2025

Most recent filing

Suzhou Zelgen Biopharmaceuticals Co Ltd Capital Reinvestment Ratio (2024–2024)

This chart tracks Suzhou Zelgen Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 1 annual periods. Check Suzhou Zelgen Biopharmaceuticals Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd (2024–2024)

Year-by-year Capital Reinvestment Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd from 2024 to 2024. For live market cap and broader valuation context, see Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) market capitalisation.

Year	Reinvestment Ratio	Operating CF (CNY)	Capital Expenditures	YoY Change
2024	2.50x	CN¥38.20 Million	CN¥95.69 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow